Ask AI
AKTi or PI3Ki in MBC
Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

European Learners: 0.25 EBAC® CE Credit

Released: April 22, 2026

References

Alpelisib [prescribing information]. East Hanover, NJ: Novartis; 2025.

Alpelisib EMA [prescribing information]. Nuremberg, Germany: Novartis; 2025.

André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929-1940.

André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32:208-217. Capivasertib [prescribing information]. Wilmington, DE: AstraZeneca; 2025.

Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after ET in metastatic breast cancer. N Engl J Med. 2024; 391:2110-2122.

Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024;42:584-604.

Bhave MA, Quintanilha JCF, Tukachinsky H, et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat. 2024;207:599-609.

Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246-3256.

Capivasertib EMA [prescribing information]. Södertälje, Sweden: AstraZeneca; 2025.

Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018; 29:1634-1657.

Dent SF, Morse A, Burnette S, et al. Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. Curr Oncol Rep. 2021;23:128.

Elacestrant [prescribing information]. New York, NY: Stemline Therapeutics, Inc; 2023.

Garber J, Cameron D, Campbell C, et al. OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/germline BRCA1 & BRCA2 pathogenic variants & high-risk HER2-negative primary breast cancer. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract GS1-09.

Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.

Hartkopf A, Grischke EM, Brucker SY. Endocrine resistant breast cancer: mechanism and treatment. Breast Care (Basel). 2020;15:347-354.

Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782-2797.

Imlunestrant [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2025.

Inavolisib [prescribing information]. South San Francisco, CA: Genentech; 2025.

Inavolisib EMA [prescribing information]. Grenzach-Wyhlan, Germany: Roche; 2025.

Jhaveri K, Im AS, Saura C, et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2025;393:151-161.

Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189-1202.

Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-763.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v2.2026. nccn.org. Accessed March 13, 2026.

Olaparib [prescribing information]. Wilmington, DE: AstraZeneca; 2025.

Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-247.

Petrucelli N, Daly MB, Pal T. BRCA1-and BRCA2-associated hereditary breast and ovarian cancer.1998 Sep 4 [updated 2025 Mar 20]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.

Sukhun SA, Temin S, Barrios CH, et al. Systemic treatment of patients with metastatic breast cancer: ASCO resource–stratified guideline. JCO Global Oncology. 2024:e2300285.

Talazoparib [prescribing information]. New York, NY; Pfizer; 2025.

Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38:1951- 1962.

Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7:1873-1881.

Trastuzumab [prescribing information]. South San Francisco, CA: Genentech; 2024.

Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388:2058-2070.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal treatment selection for patients with HR-positive locally advanced/recurrent or metastatic breast cancer. The information provided in the tool is based on the latest guidelines, indications, and expert guidance of Francois-Clement Bidard, MD, PhD; Giampaolo Bianchini, MD; Nadia Harbeck, MD; Cristina Saura Manich, MD, PhD; and Peter Schmid, MD, PhD, FRCP. The material published by Decera Clinical Education reflects the views of the reviewers or authors of the Decera Clinical Education material, not those of Decera Clinical Education, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in “Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education, including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

©2026 Decera Clinical Education, LLC. All rights reserved.

Program Content